Journey Operating Cash Flow Sales Ratio from 2010 to 2024

DERM Stock  USD 5.59  0.02  0.36%   
Journey Medical Operating Cash Flow Sales Ratio yearly trend continues to be very stable with very little volatility. Operating Cash Flow Sales Ratio is likely to grow to 0.07 this year. During the period from 2010 to 2024, Journey Medical Operating Cash Flow Sales Ratio quarterly data regression pattern had range of 23.1525 and standard deviation of  5.76. View All Fundamentals
 
Operating Cash Flow Sales Ratio  
First Reported
2010-12-31
Previous Quarter
0.06617749
Current Value
0.0695
Quarterly Volatility
5.75930753
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Journey Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Journey Medical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 1.6 M or Selling General Administrative of 53.8 M, as well as many indicators such as Price To Sales Ratio of 1.26, Dividend Yield of 0.0 or PTB Ratio of 3.5. Journey financial statements analysis is a perfect complement when working with Journey Medical Valuation or Volatility modules.
  
Check out the analysis of Journey Medical Correlation against competitors.

Latest Journey Medical's Operating Cash Flow Sales Ratio Growth Pattern

Below is the plot of the Operating Cash Flow Sales Ratio of Journey Medical Corp over the last few years. It is Journey Medical's Operating Cash Flow Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Journey Medical's overall financial position and show how it may be relating to other accounts over time.
Operating Cash Flow Sales Ratio10 Years Trend
Slightly volatile
   Operating Cash Flow Sales Ratio   
       Timeline  

Journey Operating Cash Flow Sales Ratio Regression Statistics

Arithmetic Mean(3.94)
Coefficient Of Variation(146.27)
Mean Deviation3.28
Median(4.30)
Standard Deviation5.76
Sample Variance33.17
Range23.1525
R-Value0.33
Mean Square Error31.78
R-Squared0.11
Significance0.23
Slope0.43
Total Sum of Squares464.37

Journey Operating Cash Flow Sales Ratio History

2024 0.0695
2023 0.0662
2022 -0.18
2021 -0.0345
2020 0.12
2019 0.26
2018 -5.03

About Journey Medical Financial Statements

Journey Medical investors utilize fundamental indicators, such as Operating Cash Flow Sales Ratio, to predict how Journey Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cash Flow Sales Ratio 0.07  0.07 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Journey Medical Corp is a strong investment it is important to analyze Journey Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Journey Medical's future performance. For an informed investment choice regarding Journey Stock, refer to the following important reports:
Check out the analysis of Journey Medical Correlation against competitors.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Journey Medical. If investors know Journey will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Journey Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.92)
Revenue Per Share
2.921
Quarterly Revenue Growth
(0.58)
Return On Assets
(0.17)
Return On Equity
(1.30)
The market value of Journey Medical Corp is measured differently than its book value, which is the value of Journey that is recorded on the company's balance sheet. Investors also form their own opinion of Journey Medical's value that differs from its market value or its book value, called intrinsic value, which is Journey Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Journey Medical's market value can be influenced by many factors that don't directly affect Journey Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Journey Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Journey Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Journey Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.